Some antidepressants could potentially be used to treat a wide range of diseases caused by bacteria living within cells, according to work by researchers in the Virginia Commonwealth University School of Medicine and collaborators at other institutions.
Research published in the April print edition of the journal Life Science Alliance, shows that antidepressant drugs called FIASMAs, including desipramine, amitriptyline, and nortriptyline, halt the growth or kill four different intracellular bacterial pathogens in tissue cell culture and animal models.
“Antibiotic options for diseases caused by intracellular bacteria are limited because many of these drugs cannot penetrate our cell membranes. In essence, the bacteria are protected,” said Jason Carlyon, Ph.D., leader of the study and professor in the VCU Department of Microbiology and Immunology.
Tetracycline antibiotics are most commonly prescribed to treat intracellular bacterial infections because they can cross cell membranes to reach the microbes. However, tetracyclines can cause allergic reactions in some patients and physicians advise against their use by pregnant women and children due to undesirable side effects. Additionally, antibiotic resistance in some intracellular bacteria has been reported.
“It would be highly beneficial to have a class of drugs to treat such diseases in patients for whom tetracyclines are contraindicated,” Carlyon said. “These drugs could provide an alternative to antibiotics or even be used in conjunction with them as an augmentation approach to treat infections that typically require prolonged courses of antibiotic therapy, such as those caused by Chlamydia pneumoniae and Coxiella burnetti.”
The team of researchers from VCU, Indiana University Medical Center, University of Nebraska Medical Center, University of Arkansas for Medical Sciences, and the University of South Florida, including Carlyon and lead author Chelsea Cockburn, an M.D.-Ph.D. candidate, are the first to investigate the mechanisms by which FIASMAs target multiple intracellular bacteria in detail.
The scientists tested FIASMA susceptibility for four bacterial species that cause human granulocytic anaplasmosis, a tick-borne disease that attacks white blood cells called neutrophils and can be fatal to immune compromised individuals; Q fever, a debilitating pneumonic disease; and two chlamydia infections.
FIASMAs ultimately disrupt how cholesterol, a key nutrient utilized by many intracellular pathogens, traffics inside cells to alter bacterial access to the lipid. The researchers first proved FIASMA treatment efficacy by halting anaplasmosis in both tissue culture and mice. Next, they extended their observations to demonstrate that FIASMA treatment killed the Q fever agent,Coxiella burnetii, and partially inhibited chlamydial infections in cell culture.
“Since FIASMAs influence cholesterol trafficking in the cell and cholesterol plays a role in so many facets of our biology, they have been used to treat a wide variety of conditions and diseases,” Carlyon said.
He added that the effect of FIASMAs on intracellular cholesterol ultimately bypasses the need to directly target the bacteria.
“What is so exciting about this study is that the class of drugs we evaluated targets an enzyme in our cells regulating cholesterol, not the bacteria,” Carlyon said. “I do not envision the pathogens being able to develop resistance to this treatment because it is targeting a host pathway that they very much need to grow and survive inside of the body.”
The Latest on: Alternative to antibiotics
via Google News
The Latest on: Alternative to antibiotics
- Investigational antibiotic, Cefiderocol, receives U.S. FDA Advisory Committee recommendation for approval to treat complicated UTIson October 26, 2019 at 5:49 am
Shionogi & Co., Ltd. recently announced that the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee voted to recommend approval of the investigational antibiotic ...
- 'Alternative proteins will overtake traditional meat' - experton October 26, 2019 at 3:44 am
Margaret Donnelly Twitter Email Sixty per cent of the world's protein will come from alternative protein sources by 2040, Mary Shelman, an advisor to the agribusiness programme at Harvard Business ...
- Harnessing the Power of Microbes to Fight Canceron October 25, 2019 at 4:04 am
In addition to probiotics, patients often ask their providers about alternative ways of modulating the gut microbiome using prebiotic ... Furthermore, it is not known whether bacteria that digest ...
- Multi Drug Resistant Antibiotics market Opportunities, Competitive Benchmarking and Forecast To 2025on October 24, 2019 at 10:04 pm
Apart from this, the report also enables business owners to measure buyers’ reaction to identify if they are looking for alternatives or variation. The study on Multi Drug Resistant Antibiotics market ...
- Bioinformatics Tool Tracks Individual Gut Microbial Strain Changes After Antibiotic Useon October 23, 2019 at 6:27 am
compared with single antibiotic administration. These changes were not due to a difference in growth rates, and suggest a long-term change to an alternative, stable microbiome state, Morrow suggests. ...
- It Took Just Three Weeks for Superbug to Resist Last-Resort Drug, Doctors Sayon October 22, 2019 at 5:18 pm
Just in time for Halloween, doctors in France say they witnessed a real-life horror tale involving an antibiotic-resistant superbug ... That could mean, the authors wrote, that even scary cases like ...
- Transient and long-term disruption of gut microbes after antibioticson October 22, 2019 at 6:25 am
Furthermore, the fraction of transient strains was also significantly higher in the multiple antibiotics individuals. This suggested a long-term change to an alternative stable microbiome state, ...
- The Daily Biotech Pulse: FDA Panel Backs Shionogi's Antibiotic, Hepion Surges On Data Publication, Innate Pharma IPOon October 17, 2019 at 8:48 pm
said the FDA's Antimicrobial Drugs Advisory Committee voted 14-2 to recommend approval of its investigational antibiotic cefiderocol for the treatment of complicated urinary tract infections, ...
- Researchers create antibiotic-free approach to tackle superbugon October 17, 2019 at 9:31 am
The use of antibiotic-free nanocapsules could help prevent and treat Helicobacter pylori ... Researchers said the nanocapsules are a promising candidate that could serve as an alternative or ...
- A new approach to tackle superbugson October 17, 2019 at 6:20 am
The bacteria hide under the gastric mucus layer where antibiotics do not penetrate effectively. This often leads to recurrent infections and gives rise to resistant strains. "New integral approaches ...
via Bing News